Key result
Hepatic fat linked to ~22% higher odds of carotid plaque, but not independent of overall adiposity.
Why the study?
It remains controversial whether increased hepatic fat independently contributes to cardiovascular risk.
Does increased hepatic fat independently associate with subclinical vascular disease burden in the general population?
Cross-Sectional (n=1,727)
Yes
Does increased hepatic fat independently associate with subclinical vascular disease burden in the general population?
Odds Ratio: 1.22 (95% CI 1.05–1.42)
The association between hepatic fat and subclinical vascular disease is not independent of overall adiposity, suggesting that cardiovascular risk in fatty liver disease is primarily driven by shared cardiometabolic risk factors like BMI.
Associations between hepatic fat and subclinical vascular parameters attenuate after adiposity adjustment; leaves open independent contribution to cardiovascular risk beyond cardiometabolic factors.
OBJECTIVE: It is still controversial if increased hepatic fat independently contributes to cardiovascular risk. We aimed to assess the association between hepatic fat quantified by MRI and various subclinical vascular disease parameters. DESIGN: We included two cross-sectional investigations embedded in two independent population-based studies (Study of Health in Pomerania (SHIP): n=1341; Cooperative Health Research in the Region of Augsburg (KORA): n=386). The participants underwent a whole-body MRI examination. Hepatic fat content was quantified by proton-density fat fraction (PDFF). Aortic diameters in both studies and carotid plaque-related parameters in KORA were measured with MRI. In SHIP, carotid intima-media thickness (cIMT) and plaque were assessed by ultrasound. We used (ordered) logistic or linear regression to assess associations between hepatic fat and subclinical vascular disease. RESULTS: The prevalence of fatty liver disease (FLD) (PDFF >5.6%) was 35% in SHIP and 43% in KORA. In SHIP, hepatic fat was positively associated with ascending (β, 95% CI 0.06 (0.04 to 0.08)), descending (0.05 (0.04 to 0.07)) and infrarenal (0.02 (0.01 to 0.03)) aortic diameters, as well as with higher odds of plaque presence (OR, 95% CI 1.22 (1.05 to 1.42)) and greater cIMT (β, 95% CI 0.01 (0.004 to 0.02)) in the age-adjusted and sex-adjusted model. However, further adjustment for additional cardiometabolic risk factors, particularly body mass index, attenuated these associations. In KORA, no significant associations were found. CONCLUSIONS: The relation between hepatic fat and subclinical vascular disease was not independent of overall adiposity. Given the close relation of FLD with cardiometabolic risk factors, people with FLD should still be prioritised for cardiovascular disease screening.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2021) conducted a cross-sectional in General population (n=1,727). Hepatic fat was evaluated on Subclinical vascular disease parameters (aortic diameters, carotid plaque, cIMT) (OR 1.22, 95% CI 1.05-1.42). Hepatic fat was associated with higher odds of carotid plaque (OR 1.22; 95% CI 1.05-1.42) in age- and sex-adjusted models, but this association was not independent of overall adiposity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: